Efficacy of Metacognitive Therapy for Prolonged Grief Disorder: A Randomised Control Trial.
- Conditions
- Mental Health - DepressionProlonged Grief
- Registration Number
- ACTRN12613001270707
- Lead Sponsor
- Dr Moira O'Connor
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Participant inclusion criteria will be: 1) provision of written informed consent; 2) intense symptoms of grief or PGD (as determined by PG-13) 6 months post the loss of a significant other; 3) if taking medication (namely, antidepressants or other mood stabilisers), the medication must be stable for one month prior to baseline assessment. Participants need to remain on the same dosage and medication throughout the treatment period including follow-up.
Participant exclusion criteria will be: 1) a high suicidal risk as measured by the suicidality section of the MINI (Sheehan et al., 1997); 2) participants currently undergoing other psychological treatment; and 3) a pre-existing psychiatric (excluding: anxiety & depression) or neurological history, according to the DSMIV-TR diagnostic criteria, as measured by the SCID. Participants that do not meet the inclusion criteria/or meet the exclusion criteria will be excluded from the study and will be provided referral information (such as Lifeline or Crisis Care), or for those identified with high suicidality we will consult with their psychiatrist or local general practitioner.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prolonged Grief Disorder Scale (PG-13)<br>[Baseline, post-intervention, 3-month follow-up and 6-month follow-up.];Depression Anxiety Stress Scales-21<br>[Baseline, post-intervention, 3-month follow-up and 6-month follow-up.];The Metacognitions Questionnaire-30<br>[Baseline, post-intervention, 3-month follow-up and 6-month follow-up.]
- Secondary Outcome Measures
Name Time Method The Quality of Life Enjoyment and Satisfaction Questionnaire – 18[Baseline, post-intervention, 3-month follow-up and 6-month follow-up.]